Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Unanimous 11-0
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(100)
•••
Comment by G1945Von Jun 12, 2024 6:06am
72 Views
Post# 36084147

RE:Unanimous 11-0

RE:Unanimous 11-0
Trek1701 wrote:

https://www.forbes.com/sites/joshuacohen/2024/06/11/alzheimers-disease-drug-donanemab-gets-unanimous-backing-from-fda-expert-panel/

1736 patients enrolled in p3.
25% ARIA.
5% underrepresented???
39% lower risk of progressing to the next stage.
Role of Tau biomarker.
Proposed dosing regimen may be stopped once the plaque is cleared.



"The main safety concerns of donanemab are brain swelling (edema) and micro-bleeding (hemorrhages), both known as amyloid-related imaging abnormalities, or ARIA. In the clinical trial, among people receiving donanemab, micro-bleeding occurred in 31.4% and brain swelling in 24%."

G1945V


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities